A2 to O Lung Transplants
- Conditions
- Lung TransplantABO Incompatibility
- Interventions
- Procedure: Blood group A2 donor to blood group O recipient lung transplant surgery
- Registration Number
- NCT05581745
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 10
- first lung transplant
- blood group O recipient
- low pre-operative anti-A antibody titers
- consent to study participation
- re-transplant
- multiorgan transplant
- positive virtual crossmatch at time of transplant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A2 donor transplant to O recipient Blood group A2 donor to blood group O recipient lung transplant surgery -
- Primary Outcome Measures
Name Time Method Bleeding post-op day 1-7 Incidence of malignancy 10 years C4d positivity on transbronchial biopsy samples 1 year Graft function 10 years Post-transplant anti-A antibody titers post-op day 5 or day 12 Primary graft dysfunction grade post-op day 0, 1, 2, 3 Incidence of hyperacute antibody-mediated rejection post-op day 1, 2 Incidence and severity of acute cellular rejection 1 year Chronic lung allograft dysfunction 10 years Time to death or re-transplantation 10 years Infection 10 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Toronto General Hospital, University Health Network
🇨🇦Toronto, Ontario, Canada